Lexaria Bioscience Corp. - LEXX
About Gravity Analytica
Recent News
- 04.25.2025 - Lexaria Announces $2 Million Registered Direct Offering of Common Stock
- 04.23.2025 - Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
- 04.03.2025 - Lexaria Updates its Ongoing Human Study GLP-1-H24-4
- 04.02.2025 - Lexaria’s Human GLP-1 Study #5 Begins Dosing
- 03.18.2025 - Lexaria’s DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound®
- 02.27.2025 - The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
- 02.24.2025 - Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
- 02.20.2025 - Lexaria’s Strategic Business Pursuit of DehydraTECH-Liraglutide
- 02.11.2025 - Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
- 02.06.2025 - Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway